Pharma IQ Members

Central Nervous System (CNS)

The Center For Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines. For example, fluoride toothpaste, antiperspirants, dandruff shampoos and sunscreens are all considered "drugs."

Pharma IQ News

Dr. Karl Broich, Vice President, BfArM, will discuss the new regulatory landscape  as well as projected amendments to the current guidance documents on CNS clinical trials at Optimising Clinical Development for CNS conference, 15th-16th February...

Contributor: Pharma IQ News
Tue, 01/11/2011
Helen Winsor

Dr. Wolfgang Eglmeier, Head of Clinical Operations Germany, Grünenthal GmbH, joins Helen Winsor from Pharma IQ, to discuss optimising clinical development in CNS. He outlines the main challenges when recruiting for CNS trials and some strategies...

Contributor: Helen Winsor
Thu, 01/06/2011
Market for CNS Biomarkers Predicted to Grow to $3.2 Billion by 2015

Biomarkers are now being used by a large number of companies in the biopharmaceutical industry - and one of the key therapeutic areas where they are utilised is in CNS drug development, where disorders such as Alzheimer's disease, Parkinson's...

Contributor: Pharma IQ
Wed, 12/01/2010